LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq: IPCI) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On July 24, 2017, scientists from the U.S. Food and Drug Administration (“FDA”) expressed concerns that IntelliPharmaCeutics failed to provide sufficient data about the abuse potential of its opioid painkilling drug, Rexista. On July 26, 2017, the Company announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s New Drug Application for Rexista, citing insufficient data regarding the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, shares of the Company fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.